MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the...
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the...
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative...
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs...
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 –...
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and...
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4...
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.